TG Therapeutics Inc BRIUMVI Call Transcript
Greetings. Welcome to TG Therapeutics conference call and webcast. (Operator Instructions) Please note, this conference is being recorded. At this time, I'll now turn the conference over to your host, Jenna Bosco. Jenna, you may now begin.
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the U.S. Food and Drug Administration's approval of BRIUMVI are Michael Weiss, our Chairman and Chief Executive Officer; Dr. Lawrence Steinman of Stanford University; Dr. Bruce Cree of UCSF Weill Institute for Neurosciences; and Adam Waldman, our Chief Commercialization Officer. .
Mike will begin today's call by providing some introductory comments and context around the FDA approval of BRIUMVI, following which Dr. Steinman and Cree will share the data which supported the approval and provide an overview of the prescribing information. Lastly, Adam Waldman will join us to discuss our launch and commercialization plans before we turn
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |